AI in Heart Failure Research Accelerated Into a New Phase After 2019
A large bibliometric analysis of artificial intelligence research in heart failure shows a field that moved from scattered experimentation to sustained, high-volume output in only a few years. From 2005 through 2025, investigators retrieved 4,133 records from the Web of Science Core Collection and retained 4,110 eligible publications after screening, creating a broad map of how the literature has evolved. The publication curve steepened after 2019 and reached 1,067 articles in 2025, a pace that signals more than academic curiosity. It reflects a clinical area under pressure to improve diagnosis, prognostication, and treatment selection in a syndrome that remains one of the most difficult and costly in cardiovascular medicine.
Heart failure is not a single disease process, and that complexity is part of why AI has become so attractive to researchers. Risk prediction in this population depends on imaging, laboratory markers, clinical history, hemodynamics, comorbid disease, and treatment response, often all at once. Traditional statistical methods can handle some of that burden, but they struggle when variables interact nonlinearly or when large datasets contain signals that are too diffuse for manual interpretation. AI methods, especially machine learning, offer a way to synthesize those layers into models that may better identify diagnosis, predict mortality, and support mechanism-oriented research.
Publication Growth, Geographic Concentration, and Journal Influence
The bibliometric footprint is increasingly global, but it is not evenly distributed. The United States led with 1,508 publications, followed by China with 952, placing those two countries far ahead of the rest of the field in raw output. Such concentration usually indicates where funding, data access, and interdisciplinary infrastructure have matured enough to sustain repeated modeling efforts. In practical terms, it also suggests that the evidence base is still being shaped by a limited number of research ecosystems rather than a truly worldwide network of comparable datasets.
Journal distribution points to the same pattern of rapid consolidation. Frontiers in Cardiovascular Medicine published the largest number of articles, while Circulation received the highest citation frequency. Those two metrics do not measure the same thing, and the split is informative: volume reflects where work is being published most often, while citations reflect where the field returns most frequently for influential methods, validation work, or clinically persuasive findings. In a young and expanding area, citation concentration often follows papers that help establish the vocabulary of the discipline before the literature fragments into narrower subtopics.
The keyword profile is equally telling. High-frequency terms included heart failure, machine learning, AI, risk, and mortality. Those words reveal a field focused less on theoretical novelty than on bedside consequences. The dominant research direction has centered on whether algorithms can identify patients earlier, estimate prognosis more accurately, and extract clinically meaningful features from complex data streams before decompensation becomes obvious.
Machine Learning, Imaging, and Clinical Feature Extraction Dominated the Literature
The main hotspots clustered around machine learning algorithms, medical image analysis, and clinical feature extraction. Each represents a different route to the same clinical goal. Machine learning models are used to organize large structured datasets, imaging work tries to quantify patterns in echocardiography, cardiac magnetic resonance, or other image-based inputs, and feature extraction attempts to convert messy clinical records into usable predictive signals. Together, these lines of work mirror the practical needs of heart failure care, where no single test captures the full burden of disease.
The emphasis on imaging is especially relevant. Heart failure phenotypes are often defined by structural and functional findings that already live in images, not just in chart notes or laboratory reports. AI can potentially automate interpretation, detect subtle patterns invisible to routine review, and reduce variability between readers. In prognosis, the attraction is just as strong: the ability to convert baseline images and clinical data into individualized risk estimates may improve triage, follow-up intensity, and selection of therapies. The field has moved toward those questions because clinicians need models that do more than simply classify disease; they need tools that can influence decisions before clinical decline becomes irreversible.
One sentence captures the shift plainly: the literature now centers on prediction rather than proof of concept.
External Validation and Multicenter Datasets Remain the Pressure Point
Despite the surge in publications, the analysis points to a familiar weakness in AI-driven medicine: models are only as credible as the data used to train and test them. Future work should rely more heavily on multicenter data for external validation and on the construction and sharing of multicenter, multimodal datasets. In a syndrome as heterogeneous as heart failure, a model trained in one center may perform well locally while losing accuracy when applied to different populations, different imaging protocols, or different treatment patterns.
That problem is not academic. It determines whether AI can move from research dashboards into routine clinical workflows. A prognostic model that looks strong in internal testing may still fail when exposed to broader variation in age, comorbidity burden, device use, race, renal disease, or treatment pathways. Multimodal datasets are especially important because heart failure does not announce itself through a single source of truth. Ejection fraction, natriuretic peptides, imaging, medication history, hospitalization patterns, and symptom trajectory all matter, and robust models will need to integrate more than one data type to remain clinically usable.
The publication surge also carries a cautionary message for clinicians. Volume alone does not establish clinical maturity. A field can grow quickly while still depending on narrow cohorts, retrospective data, or untested performance metrics. The strength of this bibliometric map is that it reveals where the field is moving; its limitation is that bibliometrics cannot determine whether the resulting models actually improve outcomes at the bedside.
What the Research Map Means for Heart Failure Care
The broader trajectory is straightforward: AI research in heart failure has matured into a substantial interdisciplinary enterprise with clear clusters around diagnosis, prognosis, and mechanistic analysis. The scale of publication growth since 2019 suggests that investigators now see this as a durable clinical research domain rather than a temporary technology trend. For physicians and researchers, the most relevant implication is not the number of papers produced but the kind of evidence still missing. External validation, dataset sharing, and multimodal integration will decide whether these tools remain promising prototypes or become dependable clinical instruments.
For now, the bibliometric pattern shows a field in expansion, with machine learning and imaging at the center and mortality prediction still the recurring endpoint. The next stage will depend on whether the literature can move from local performance to generalizable utility across centers, populations, and real-world care pathways.